Pfizer reaffirms FY2026 guidance after CFO transition; revenue $59.5-$62.5B, adj. EPS $2.80-$3.00

PFIZER INC

Reaffirms FY2026 revenue guidance of $59.5-$62.5 billion.
Reaffirms FY2026 adjusted diluted EPS guidance of $2.80-$3.00.
Reaffirmation follows CFO transition announcement on June 18, 2026.
Guidance originally introduced Dec 16, 2025 and reaffirmed on Q1 2026 earnings call May 5, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.